ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of...

ChromaDex Establishes a Blanket Purchase Agreement With the National
Institutes of Health

The Blanket Purchase Agreement will expedite the purchasing process for groups
within the National Institutes of Health.

IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC
Bulletin Board: CDXC) a leader in phytochemical reference standards and
contract research, announced today that the National Institutes of Health
established a Blanket Purchase Agreement (BPA) with the Company. The
Agreement covers all products and services offered by ChromaDex. This includes
botanical reference materials, phytochemicals, bulk chemical production,
analytical testing services, analytical method development, contract research,
isolation of compounds, chemical synthesis and natural product libraries.

The BPA makes it easier for the various Institutes within NIH to do business
with ChromaDex.

"We are honored to be recognized by the National Institutes of Health with the
issuance of a Blanket Purchase Agreement to ChromaDex," said Frank Jaksch,
co-founder and CEO of ChromaDex. "There is considerable work taking place at
NIH in the areas of natural products, dietary supplements and alternative
medicines. As a leader in this field, ChromaDex will be working closely with
NIH to provide products and services to support their efforts."

About National Institutes of Health
NIH is the steward of medical and behavioral research for the Nation. Its
mission is science in pursuit of fundamental knowledge about the nature and
behavior of living systems and the application of that knowledge to extend
healthy life and reduce the burdens of illness and disability. Composed of 27
Institutes and Centers, the NIH provides leadership and financial support to
researchers in every state and throughout the world. For over a century, the
National Institutes of Health has played an important role in improving the
health of the nation.

About ChromaDex
ChromaDex is a world leader in the development of Phytochemical and Botanical
Reference Standards and the creation of associated intellectual property.
ChromaDex is committed to sustainable "Green chemistry" and provides the
dietary supplement, food, beverage, nutraceutical and cosmetic industries with
the analytical tools and services to meet product regulatory, quality,
efficacy and safety standards.

Forward-Looking Statements
Any statements that are not historical facts contained in this release are
forward-looking statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such statements
involve risks and uncertainties, including but not limited to ability to
market, produce and sell the referenced ingredients, risks relating to product
and customer demand, market acceptance of our products, the effect of economic
conditions both nationally and internationally, ability to protect our
intellectual property rights, impact of any litigation or infringement actions
brought against us, competition from other providers and products, risks in
product development, our ability to raise capital to fund continuing
operations, the ability to complete transactions, and other factors discussed
from time to time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any forward-looking
statement for events or circumstances after the date on which such statement
is made except as required by law.

SOURCE ChromaDex Corp.

ChromaDex Corporation, +1-949-419-0288, Fax, +1-949-419-0294,
info@chromadex.com; or Investors, Parag Dave, +1-619-849-5378,
pdave@pnlifesciences.com, or Media, Megan Lavine, +1-619-849-5388,
mlavine@pnlifesciences.com, both of Porter Novelli Life Sciences, for
ChromaDex Corp.